Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 1 · 14.3%High 4 · 57.1%

Confirmed SARS‐CoV‐2 infection

The review found no eligible studies for this question.

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Confirmed symptomatic COVID‐19b

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39058 participants
High

Severe or critical COVID‐19

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39058 participants
High

All‐cause mortalityb

AD26.COV2.S – Janssen Pharmaceutical Companies leads to lower all‐cause mortalityb compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.25 [0.09, 0.67]
1 study · 43783 participants
High

Serious adverse eventsb

AD26.COV2.S – Janssen Pharmaceutical Companies showed no clear difference in serious adverse eventsb compared with placebo (moderate certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 0.92 [0.69, 1.22]
1 study · 43783 participants
Moderate

Systemic reactogenicity events

AD26.COV2.S – Janssen Pharmaceutical Companies leads to higher systemic reactogenicity eventse compared with placebo (high certainty).

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
RR 1.83 [1.29, 2.6]
2 studies · 7222 participants
High

Any adverse eventh

1 finding from 1 review

Efficacy and safety of COVID‐19 vaccines 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 7222 participants
Low